je.st
news
Tag: allergan
Allergan generic drug firm bought for $40.5B
2015-07-28 00:44:29| Biotech - Topix.net
Israel's Teva Pharmaceutical Industries Ltd. said Monday it is purchasing Dublin-based Allergan PLC's generic pharmaceuticals business for $40.5 billion, in what Israeli analysts called the largest-ever acquisition by an Israeli company. Statements from both companies say the deal will see Allergan receive $33.75 billion in cash and shares of Teva valued Monday at $6.75 billion.
Tags: firm
drug
bought
generic
Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino...
2015-07-28 00:44:28| Biotech - Topix.net
Allergan plc and KYTHERA Biopharmaceuticals, Inc. today announced that the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to Allergan's pending acquisition of KYTHERA. On July 6, 2015, each of Allergan and KYTHERA filed a Pre-Merger Notification and Report Form pursuant to the HSR Act with the Antitrust Division of the U.S. Department of Justice and the FTC.
Tags: early
termination
announce
allergan
Allergan to acquire Naurex as Teva talks continue
2015-07-27 07:03:51| Biotech - Topix.net
Allergan PLC, the Dublin-based pharmaceutical giant, announced Sunday it has agreed to buy Naurex, a developer of drugs for depression and other central nervous system disorders, for $560 million. Naurex, based in Evanston, Illinois, is privately held.
Tags: continue
talks
acquire
teva
Allergan may be broken up
2015-07-25 05:38:47| Biotech - Topix.net
Allergan Plc, the $121 billion pharmaceutical company created through a merger with Actavis Plc, is exploring a breakup of the company, people with knowledge of the matter said. Allergan is leaning toward keeping the branded-drugs business and spinning off or selling parts or all of the generics business, said the people, who asked not to be identified because the information is private.
Allergan Cost Synergies On Track For Large Upside
2015-03-15 01:50:25| Biotech - Topix.net
AGN is positioned well to take advantage of attractive industry growth; we believe management is conservative about its estimates on revenue projections. After the $66 billion dollar Activis and Allergan deal, post merger synergies will arise.
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] next »